Literature DB >> 11972982

Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.

S M Agwale1, C Zeh, K E Robbins, L Odama, A Saekhou, A Edubio, M Njoku, N Sani-Gwarzo, M S Gboun, F Gao, M Reitz, D Hone, D Pieniazek, C Wambebe, M L Kalish.   

Abstract

We conducted a national molecular epidemiologic survey of HIV-1 strains in Nigeria to determine the most prevalent subtype(s) for use in developing candidate vaccines. A total of 230 HIV-1-positive blood samples collected from 34 of the 36 Nigerian states were analyzed by our modified env gp41-based heteroduplex mobility assay (HMA) and/or gp41 sequencing and analysis. Overall, 103 (44.8%) were subtype A, 125 (54.3%) were subtype G, one (0.4%) was subtype C, and one (0.4%) was subtype J, and one (0.4%) was unclassifiable. To further characterize Nigerian viruses to aid in strain selection for candidate vaccines, one gp41 subtype G and five gp41 subtype A strains were selected for full envelope sequencing. The one subtype G sequence had consistent phylogenies throughout gp160, using programs to detect recombination. However, all five sequences that were primarily subtype A in gp41 were found to be recombinant viruses. Two of the five (40%) were A/G/J mosaics with common breakpoints. The remaining three gp160 recombinants all had their own unique break points: two A/? and one A/?/G, however, all five had the majority of their mosaic breakpoints occurring in gp41. None of the five were consistent with the circulating recombinant form (CRF)02_AG strain previously reported to be prevalent in West Africa. In conclusion, we showed a clear dominance and widespread distribution of gp41 subtypes A and G in fairly equal proportions, suggesting that vaccines designed for use in this geographic locale should incorporate the gene(s) of both subtypes. However, appreciating the magnitude of diversity of HIV-1 strains in Nigeria may require sequencing and analysis of longer gene regions for the identification of prevalent or emerging CRFs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972982     DOI: 10.1016/s0264-410x(02)00059-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

2.  Characterization of acute HIV-1 infection in high-risk Nigerian populations.

Authors:  Man Charurat; Abdulsalami Nasidi; Kevin Delaney; Ahmed Saidu; Taelisha Croxton; Prosanta Mondal; Gambo Gumel Aliyu; Niel Constantine; Alash'le Abimiku; Jean K Carr; John Vertefeuille; William Blattner
Journal:  J Infect Dis       Date:  2012-02-21       Impact factor: 5.226

3.  HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria.

Authors:  Gambo Aliyu; Mukhtar Mohammad; Ahmed Saidu; Prosanta Mondal; Man Charurat; Alash'le Abimiku; Abdulsalami Nasidi; William Blattner
Journal:  AIDS Care       Date:  2010-10

Review 4.  Evolution and diversity of HIV-1 in Africa--a review.

Authors:  Maria A Papathanasopoulos; Gillian M Hunt; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003       Impact factor: 2.332

5.  Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.

Authors:  Simon M Agwale; Joseph C Forbi; Frank Notka; Terri Wrin; Jens Wild; Ralf Wagner; Hans Wolf
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

6.  Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates.

Authors:  Hannah O Ajoge; Michelle L Gordon; Tulio de Oliveira; Taryn N Green; Sani Ibrahim; Oladapo S Shittu; Stephen O Olonitola; Aliyu A Ahmad; Thumbi Ndung'u
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

7.  Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Authors:  Karen S Slobod; Chris Coleclough; Scott A Brown; John Stambas; Xiaoyan Zhan; Sherri Surman; Bart G Jones; Amy Zirkel; Pamela J Freiden; Brita Brown; Robert Sealy; Mattia Bonsignori; Julia L Hurwitz
Journal:  AIDS Res Ther       Date:  2005-04-28       Impact factor: 2.250

8.  Origin and Population Dynamics of a Novel HIV-1 Subtype G Clade Circulating in Cape Verde and Portugal.

Authors:  Isabel Inês M de Pina-Araujo; Edson Delatorre; Monick L Guimarães; Mariza G Morgado; Gonzalo Bello
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

9.  Spatiotemporal dynamics of the HIV-1 subtype G epidemic in West and Central Africa.

Authors:  Edson Delatorre; Daiana Mir; Gonzalo Bello
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

10.  Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG.

Authors:  Richard A Heipertz; Ojor Ayemoba; Eric Sanders-Buell; Kultida Poltavee; Phuc Pham; Gustavo H Kijak; Esther Lei; Meera Bose; Shana Howell; Anne Marie OʼSullivan; Adam Bates; Taylor Cervenka; Janelle Kuroiwa; Akindiran Akintunde; Onyekachukwu Ibezim; Abraham Alabi; Obumneke Okoye; Mark Manak; Jennifer Malia; Sheila Peel; Mohammed Maisaka; Darrell Singer; Robert J O'Connell; Merlin L Robb; Jerome H Kim; Nelson L Michael; Ogbonnaya Njoku; Sodsai Tovanabutra
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.